Lanifibranor—a pan-agonist affecting PPARα, PPARγ and PPARβ/δ—is currently showing promising results, achieving NASH resolution and fibrosis regression in a phase IIb clinical trial (NCT03008070) [154]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.